Functional avidity: a measure to predict the efficacy of effector T cells?
Details
Download: BIB_B0CB84A1CD5B.P001.pdf (1815.86 [Ko])
State: Public
Version: author
State: Public
Version: author
Serval ID
serval:BIB_B0CB84A1CD5B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Functional avidity: a measure to predict the efficacy of effector T cells?
Journal
Clinical and Developmental Immunology
ISSN
1740-2530 (Electronic)
ISSN-L
1740-2522
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
2012
Pages
153863
Language
english
Notes
Publication types: Journal Article WOS Document Type: Review
Abstract
The functional avidity is determined by exposing T-cell populations in vitro to different amounts of cognate antigen. T-cells with high functional avidity respond to low antigen doses. This in vitro measure is thought to correlate well with the in vivo effector capacity of T-cells. We here present the multifaceted factors determining and influencing the functional avidity of T-cells. We outline how changes in the functional avidity can occur over the course of an infection. This process, known as avidity maturation, can occur despite the fact that T-cells express a fixed TCR. Furthermore, examples are provided illustrating the importance of generating T-cell populations that exhibit a high functional avidity when responding to an infection or tumors. Furthermore, we discuss whether criteria based on which we evaluate an effective T-cell response to acute infections can also be applied to chronic infections such as HIV. Finally, we also focus on observations that high-avidity T-cells show higher signs of exhaustion and facilitate the emergence of virus escape variants. The review summarizes our current understanding of how this may occur as well as how T-cells of different functional avidity contribute to antiviral and anti-tumor immunity. Enhancing our knowledge in this field is relevant for tumor immunotherapy and vaccines design.
Pubmed
Web of science
Open Access
Yes
Create date
31/12/2012 12:19
Last modification date
20/08/2019 15:19